NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2023 - November 30, 2023. The report is available on the company's website: https://www.nextcellpharma.com/en/investorsfinancial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.
First quarter (2023-09-01 until 2023-11-30)
- Operating Income amounted to 4,695 (3,012) TSEK, of which
Cellaviva amounted to 4,218 (2,137) TSEK.
- Operating result amounted to -9,796 (-8,918) TSEK.
- Earnings per share* amounted to -0.28 (-0.26) SEK.
- Cash and bank amounted to 40,428 (88,258) TSEK.
- Solidity** amounted to 82.2 (92.7)
Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the fourth quarter 2023/2024: 34,379,523 (34,379,523) shares. Average number of shares for the full year 2022/2023: 34,379,523 (34,379,523847) shares. Number of shares in NextCell as of November 30, 2023: 34,379,523 (34,379,523) shares.
**Solidity: Equity to total balance sheet.
Significant events in the first quarter
- NextCell Pharma AB ("NextCell" or "the company") announces that the company has signed an agreement with the Finnish biotechnology company Linio to warehouse and distribute Tience® in Sweden. The value of the agreement for the first year amounts to approximately 400 000 SEK in fixed remuneration and a variable remuneration per product delivered. Tience is a tissue product that is injected to combat scarring and can also be used for aesthetic purposes such as skin rejuvenation and to combat wrinkles. The product is marketed and sold by Linio to clinics and hospitals.
Significant events after the reporting period
- At the end of January, NextCell published an update on the ongoing clinical trials. The largest ongoing study - ProTrans Young, which includes 66 patients - is progressing well.
This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 25-01-2024 07:30 CET.
For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com
Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma
For more information about Cellaviva, please contact
Sofie Falk Jansson, Head of Cellaviva
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se
Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva
Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser.
About NextCell Pharma AB
NextCell is a cell therapy company in Phase 2 trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a Phase 3 trial. In addition to type 1 diabetes, ProTrans is used in two clinical trials for COVID-19, in Örebro and in Montreal, Canada. The company is in the process of establishing its own GMP-facility for the production of ProTrans. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology, and 100% of Cellaviva, Scandinavia's largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use.
